We recently compiled a list of the 14 Best Performing Dividend Stocks To Buy Now. In this article, we are going to take a ...

The TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis, according to ...

Bullish option flow detected in Bristol Myers ( BMY) Squibb with 17,811 calls trading, 1.1x expected, and implied vol increasing over 2 points to 28.33%. May-25 60 calls and 3/14 weekly 63 calls are ...

Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...

The European Commission (EC) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in combination with the ...

Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing ...

Bristol Myers Squibb's Phase 3 POETYK PsA-2 trial shows Sotyktu improved psoriatic arthritis symptoms, meeting primary and secondary endpoints at Week 16.

European Commission approves Bristol Myers Squibb’s Opdivo plus Yervoy for first-line treatment of adult patients with unresectable or advanced HCC: Princeton, New Jersey Monday ...

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...

US pharma major Bristol Myers Squibb has announced positive data from the pivotal Phase III POETYK PsA-2 trial evaluating the ...

These high-yield dividend stocks are outstanding ideas for growth and income investors now, as they hold up better during a ...

J&J's head of immunodermatology Liza O'Dowd said that the "robust results" with its oral IL-23 drug have the potential to ...